Metabolic syndrome in pediatric cancer survivors: A mechanistic review

Authors

  • Galit P. Rosen MD,

    Corresponding author
    1. Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, Arizona
    2. Department of Child Health, UA College of Medicine-Phoenix, Phoenix, Arizona
    • Correspondence to: Galit Rosen, MD, Phoenix Children's Hospital, Center for Cancer and Blood Disorders, 1919 E. Thomas Rd, Phoenix, AZ 85016.

      E-mail: grosen@phoenixchildrens.com

    Search for more papers by this author
  • Hoai-Trinh Nguyen MD,

    1. Department of Pediatrics, Phoenix Children's Hospital, Phoenix, Arizona
    Search for more papers by this author
  • Gabriel Q. Shaibi PhD

    1. Division of Endocrinology and Diabetes, Phoenix Children's Hospital, Phoenix, Arizona
    2. College of Nursing and Health Innovation, Arizona State University, Phoenix, Arizona
    Search for more papers by this author

  • Conflict of interest: Nothing to declare.

Abstract

Pediatric cancer survivors have increased risk of obesity, hypertension, dyslipidemia, and type 2 diabetes, leading to premature cardiovascular disease (CVD). Multiple tissues that are involved in glucose homeostasis and lipid metabolism are adversely affected by chemotherapy. This review highlights the relevant tissue and molecular end-organ effects of therapy exposures and synthesizes the current understanding of the mechanisms underlying CVD risk in this vulnerable population. The review also approaches the topic from a developmental perspective, with the goal of providing a translational approach to identifying the antecedents of overt CVD among survivors of pediatric cancer. Pediatr Blood Cancer 2013;60:1922–1928. © 2013 Wiley Periodicals, Inc.

Ancillary